Zetia Cost in New Mexico 2026: Cash Price, Medicaid, Insurance, and Compounded Options

What Does Zetia Actually Cost in New Mexico in 2026?

Brand-name Zetia lists at approximately $380 per month in New Mexico, but almost no cash-pay patient needs to pay that price. Generic ezetimibe 10 mg tablets, manufactured by multiple companies since the patent expiry, retail for around $15 per month at most major New Mexico pharmacies including Walgreens, CVS, Walmart, and Smith's. Discount platforms such as GoodRx and RxSaver frequently show prices below $10 for a 30-day supply at specific ZIP codes in Albuquerque, Santa Fe, and Las Cruces.

The gap between the brand list price and the generic cash price is one of the largest in the cholesterol drug class. That $365 monthly difference exists because FDA-approved generic ezetimibe has been on the U.S. market since 2017 and is now manufactured by more than a dozen companies, keeping prices highly competitive. Patients who are still being dispensed brand-name Zetia at full list price are almost always in a situation where either their pharmacy has not substituted automatically or their prescriber wrote "dispense as written."

For most New Mexico residents without prescription drug insurance, the practical decision is simple: ask for generic ezetimibe, not Zetia by name. A 90-day supply at many chains runs $30 to $45 cash, which equals $10 to $15 per month. The FDA approved ezetimibe as a selective cholesterol absorption inhibitor in 2002, and the generics carry the identical active ingredient at the same 10 mg dose. The FDA prescribing information confirms therapeutic equivalence of approved generics.

Does New Mexico Medicaid Cover Zetia or Generic Ezetimibe?

New Mexico Medicaid (Centennial Care) does not cover brand-name Zetia. Generic ezetimibe coverage under Centennial Care depends on the managed care organization (MCO) plan a member is enrolled in, and coverage tiers shift annually, so members should confirm their 2026 formulary directly with their MCO.

New Mexico Medicaid contracts with four managed care organizations for Centennial Care: Blue Cross Blue Shield of New Mexico, Molina Healthcare of New Mexico, Presbyterian Health Plan, and Western Sky Community Care. Each MCO maintains its own drug formulary. Ezetimibe generic has appeared on some of these formularies at Tier 2 or Tier 3 with a modest copay, but not uniformly across all four plans. Calling the member services number on the back of your Medicaid card and asking specifically for "ezetimibe 10 mg tablet" coverage status is the only reliable way to get a 2026 answer.

If your MCO does not cover ezetimibe and your prescriber believes it is medically necessary (for example, because you cannot tolerate statins), a prior authorization or step-therapy exception request is the standard pathway. The American College of Cardiology and American Heart Association 2018 cholesterol guidelines note that ezetimibe is a reasonable second-line agent in high-risk patients who cannot achieve sufficient LDL-C lowering with statins alone. Grundy SM et al. 2018 AHA/ACC Cholesterol Guideline, Circulation. Documenting statin intolerance or a maximally tolerated statin dose is the strongest lever for a successful prior authorization.

Why Ezetimibe Is Prescribed: The IMPROVE-IT Evidence

Ezetimibe lowers LDL cholesterol by blocking the Niemann-Pick C1-Like 1 (NPC1L1) protein in the small intestine, reducing cholesterol absorption by roughly 50 to 60 percent. Used alone, it typically lowers LDL-C by 18 to 22 percent. Combined with a statin, the additive effect can cut LDL-C by an additional 20 to 25 percent on top of what the statin achieves alone.

The landmark IMPROVE-IT trial (N=18,144) published in the New England Journal of Medicine in 2015 settled a decade-long debate about whether lowering LDL-C with a non-statin agent actually reduced hard cardiovascular events, not just a lab number. Patients with recent acute coronary syndrome were randomized to simvastatin 40 mg plus ezetimibe 10 mg versus simvastatin 40 mg plus placebo. At a median follow-up of 6 years, the combination arm reduced LDL-C to a mean of 53.7 mg/dL versus 69.5 mg/dL in the placebo arm, and the primary endpoint (cardiovascular death, major coronary event, or nonstroke) occurred in 32.7 percent of the ezetimibe group versus 34.7 percent of the placebo group, an absolute risk reduction of 2.0 percentage points (hazard ratio 0.936 to 95% CI 0.89 to 0.99, P=0.016). Cannon CP et al. NEJM 2015; IMPROVE-IT.

That 2.0 percentage point absolute reduction over 6 years is modest but statistically significant and clinically meaningful in a high-risk post-ACS population. The trial's key message, as summarized by lead author Dr. Christopher Cannon, was direct: "These results support the 'lower is better' hypothesis for LDL cholesterol and validate the use of ezetimibe as an add-on therapy to statins."

Ezetimibe is generally well-tolerated. Rates of myalgia and hepatic enzyme elevation in IMPROVE-IT did not differ meaningfully between the ezetimibe and placebo arms, which matters for patients who have already experienced statin-related muscle symptoms.

Commercial Insurance Coverage for Zetia in New Mexico

Most New Mexico commercial insurance plans, including those sold through beWellnm (the state ACA marketplace), cover generic ezetimibe at Tier 1 or Tier 2, meaning a copay between $0 and $50 per month for most enrollees. Brand-name Zetia, when it appears on formularies at all, typically sits at Tier 3 or Tier 4 with a coinsurance or flat copay that still leaves the patient paying $60 to $120 per month even with insurance.

The practical rule: always check whether your plan covers the generic first. Pharmacy benefit managers typically auto-substitute the generic anyway, but "dispense as written" prescriptions and certain specialty pharmacy routing arrangements can override that. If you are paying more than $20 per month for ezetimibe on commercial insurance, ask your pharmacist whether a generic is dispensable under your plan and whether a 90-day mail-order supply reduces your tier copay.

Large employers in New Mexico, including state government employees under the New Mexico Public Schools Insurance Authority (NMPSIA) and the State Personnel Office Group Benefits Plan, have included generic ezetimibe on standard formularies in recent plan years. Government employees should check their 2026 Summary Plan Description for current tier placement.

Merck offers a savings card for brand-name Zetia for commercially insured patients, which can reduce the monthly out-of-pocket cost to as low as $18 per month for eligible patients. Eligibility is limited to commercial insurance only. Patients on Medicare Part D, Medicaid, TRICARE, or any other federal or state government health program do not qualify for manufacturer savings cards under federal anti-kickback rules. To enroll, visit the Merck patient assistance page or ask your pharmacist for the card code at the point of sale.

Is Compounded Ezetimibe Legal in New Mexico?

Yes. Licensed 503A compounding pharmacies in New Mexico may legally compound ezetimibe for individual patients when a valid, patient-specific prescription is presented. This is permitted under Section 503A of the Federal Food, Drug, and Cosmetic Act, which governs traditional compounding pharmacies that dispense to individual patients on a prescription-by-prescription basis.

A 503A pharmacy differs from a 503B outsourcing facility. 503B facilities compound in bulk for health systems without patient-specific prescriptions and are subject to FDA registration and cGMP oversight. New Mexico has several licensed 503A pharmacies operating in Albuquerque, Santa Fe, and Roswell that compound cholesterol-related medications.

Compounded ezetimibe is not FDA-approved in the same sense that a manufactured generic is. The compounded product does not go through the FDA's abbreviated new drug application (ANDA) review process, which means bioequivalence has not been independently confirmed for the specific compounded formulation. The New Mexico Board of Pharmacy regulates 503A compounders in the state and requires compliance with USP Chapter 795 standards for non-sterile compounding. New Mexico Board of Pharmacy information is accessible through the state's licensing portal; federal 503A framework is described in FDA guidance at FDA.gov.

Some telehealth and direct-care practices in New Mexico route ezetimibe prescriptions to 503A compounders as part of a bundled subscription model, resulting in $0 out-of-pocket cost to the patient for the medication itself (the subscription fee covers the compound). Whether this model provides value depends on the subscription price versus the ~$15 cash cost of generic ezetimibe at retail.

The bottom line on compounding for most New Mexico patients: it is legal with a prescription, but the $15 generic retail price makes compounding a cost advantage only within a bundled telehealth plan or when a specific formulation (such as a combination compound) is clinically indicated.

Telehealth Prescribing of Ezetimibe in New Mexico

New Mexico allows telehealth prescribing of ezetimibe. The state follows a synchronous audio-video standard for controlled substances, but ezetimibe is a non-controlled prescription medication, so it can be prescribed via asynchronous (store-and-forward) telehealth visits in addition to live video visits. This is consistent with the New Mexico Medical Practice Act and the state's telehealth rules under the New Mexico Human Services Department.

Platforms operating in New Mexico, including HealthRX, can evaluate a patient's lipid panel, cardiovascular risk score, and current medication list, then issue a prescription for ezetimibe 10 mg without an in-person visit. The prescriber must hold a valid New Mexico medical license. Lab results (a current lipid panel) are typically required to initiate therapy; most platforms accept results from LabCorp, Quest, or a patient's local PCP within the past 12 months.

After the initial telehealth consultation, follow-up lipid testing is generally recommended at 6 to 8 weeks to confirm the LDL-C response. The 2018 AHA/ACC guideline recommends rechecking fasting lipids 4 to 12 weeks after initiating or adjusting lipid-lowering therapy to assess adherence and therapeutic response. Grundy SM et al. 2018 AHA/ACC Cholesterol Guideline.

One practical consideration: if a telehealth platform bundles the ezetimibe prescription with a 503A-compounded product, confirm that the New Mexico pharmacy filling the prescription holds a current New Mexico Board of Pharmacy license. Out-of-state compounders shipping into New Mexico must also hold a New Mexico non-resident pharmacy license.

How to Pay the Least for Ezetimibe in New Mexico: A Step-by-Step Framework

The path to the lowest possible ezetimibe cost in New Mexico depends on your insurance status. The following decision logic applies to 2026 pricing as reported across New Mexico retail pharmacies and telehealth platforms.

Step 1: You have commercial insurance. Check whether generic ezetimibe 10 mg is on your formulary. If yes, fill a 90-day supply through mail order to minimize tier copays, often $0 to $30 per quarter. If your plan only lists brand Zetia and places it at Tier 3 or above, ask your prescriber to write "ezetimibe 10 mg tablet, generic substitution permitted" and confirm dispensing at your pharmacy.

Step 2: You have New Mexico Medicaid (Centennial Care). Call your MCO and confirm whether ezetimibe generic is on the 2026 formulary. If covered, your copay is likely $0 to $4 per month. If not covered and your prescriber documents medical necessity, pursue a prior authorization. If prior authorization is denied, the cash price of ~$15 per month at retail is a reasonable fallback for a medication this inexpensive.

Step 3: You are uninsured or pay cash. Go directly to the generic. Use GoodRx or a similar discount platform to compare prices at pharmacies near your ZIP code. Walmart and Costco have historically offered the lowest ezetimibe cash prices in New Mexico, sometimes as low as $9 for a 30-day supply. A 90-day supply reduces per-unit cost further.

Step 4: You use a telehealth or direct-care subscription. If ezetimibe is included in a bundled subscription at no additional drug cost, compare the total subscription fee against the ~$15/month retail generic price. Bundling makes financial sense only if you are also receiving other services (lab monitoring, cardiovascular risk assessment, medication management) through the same subscription.

Step 5: You are on Medicare Part D. Medicare Part D plans vary. Generic ezetimibe often falls at Tier 1 or Tier 2 under most Part D formularies, with copays under $10 per month. The Medicare Extra Help (Low Income Subsidy) program can reduce or eliminate Part D cost-sharing for qualifying New Mexico residents. Contact the New Mexico State Agency on Aging or call 1-800-MEDICARE for Extra Help eligibility determination.

Ezetimibe Dosing, Safety, and Monitoring in New Mexico Clinical Practice

Ezetimibe is prescribed as a single 10 mg oral tablet taken once daily, with or without food, at any time of day. No dose adjustment is required for mild to moderate hepatic impairment. The drug is not recommended in patients with moderate to severe hepatic impairment because hepatic glucuronidation is the primary metabolic pathway and drug exposure increases substantially in that population.

Drug interactions worth knowing: bile acid sequestrants (cholestyramine, colesevelam) can reduce ezetimibe absorption by roughly 55 percent if taken simultaneously. The dosing solution is to take ezetimibe at least 2 hours before or at least 4 hours after a bile acid sequestrant dose. Cyclosporine increases ezetimibe plasma concentrations approximately 3.4-fold; patients on cyclosporine should be monitored for ezetimibe-related adverse effects. FDA prescribing information for ezetimibe covers these interactions in detail.

Common adverse effects reported in clinical trials include upper respiratory tract infection (occurring in about 4 percent of patients in IMPROVE-IT), arthralgia, and diarrhea. Myopathy and rhabdomyolysis are rare but have been reported, primarily in patients also taking statins, fibrates, or cyclosporine.

Baseline liver function tests are not required before starting ezetimibe as monotherapy per current FDA labeling, though they are recommended when combining ezetimibe with a statin. A fasting lipid panel at 6 to 8 weeks after initiation confirms LDL-C response and guides any dose adjustment of concomitant statin therapy.

New Mexico-Specific Resources for Ezetimibe Access

New Mexico patients who need help covering prescription costs beyond GoodRx discounts have several state-specific resources.

The New Mexico Human Services Department administers Medicaid enrollment and can assist patients in determining whether they qualify for Centennial Care. Enrollment is year-round for Medicaid (not limited to open enrollment periods). Patients near the income threshold for Medicaid who do not qualify may be eligible for APTC-subsidized ACA plans through beWellnm, where generic ezetimibe is typically covered.

The NeedyMeds database lists patient assistance programs, though most manufacturer programs (including Merck's Zetia assistance program) exclude generic ezetimibe because it is not a branded product. For patients who genuinely cannot afford the $15 cash price, the generic ezetimibe may qualify under the 340B Drug Pricing Program at federally qualified health centers (FQHCs) in New Mexico. FQHCs in the state include First Choice Community Healthcare, La Familia Medical Center, and Hidalgo Medical Services. Under 340B, the dispensing price at FQHC-affiliated pharmacies can be substantially below retail.

New Mexico also has a State Pharmacy Assistance Program (SPAP) framework for Medicare beneficiaries that wraps around Part D coverage for certain drugs. Ezetimibe's status under that program shifts annually and should be confirmed with the New Mexico Aging and Long-Term Services Department.